Search General Info
Search Education
Search Partnering Companies
photo
Speaker

Sean Xie, MBA, MD, PhD

FOUNDER/CSO & CHAIRMAN OF THE BOARD, ID4PHARMA
Mars, Pennsylvania, United States
Dr. Sean Xie (Presentor) is a Founder/CSO and Chairman of the Board of ID4Pharma. He is an inventor of the international patent technologies. Dr Xie also serves as a Charter Member of the Science Board to the US FDA. Dr Xie is Associate Dean of Reesearch Innovation, and Professor/PI of Medicinal Chemistry Biology Lab at University of Pittsburgh School of Pharmacy, with over 200 peer-reviewed publications about his innovation discoveries. Among these, He has reported first-in-class SQSTM1/p62 target-specific small molecules with therapeutics potential for anti-tumor multiple myeloma. Among his published work, Xie has published his pioneer innovation work in high impact factor jourhnals, including: Cell, Leukemia, Nat Comm, PNAS, JMC, as proof-of-evidences:

1) “p62/SQSTM1/Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis.” Nat Commun. 2017; 8(1):102.
2) “Blocking the ZZ Domain of Sequestosome1/p62 Suppresses Myeloma Cell Growth and Osteoclast Formation In Vitro and Induces Dramatic New Bone Formation in Myeloma-Bearing Bones In Vivo” Leukemia, 2016;30:390-8.
3) “N-terminal arginylation generates a bimodal degron that modulates autophagic proteolysis.” PNAS 2018; 115(12):E2716-E24.
4) “XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation Suppression.” Frontiers in Endocrinology. 2018;9:344.
Speaking In
[On Demand]
ID4Pharma (or ID4) is a University-Pittsburgh technology-based startup and is a leading innovator…
[On Demand]
ID4Pharma (or ID4) is a University-Pittsburgh technology-based startup and is a leading innovator…